121 related articles for article (PubMed ID: 31693615)
1. Optimized CT Attenuation and SUV Prediction Thresholds for Differentiating Enostoses From Untreated and Treated Metastases on Attenuation-Corrected 18F-FDG PET/CT.
Lee HT; Pryma DA; Sebro R
Clin Nucl Med; 2020 Jan; 45(1):32-37. PubMed ID: 31693615
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of CT Attenuation Measurement for Differentiating Treated Osteoblastic Metastases From Enostoses.
Elangovan SM; Sebro R
AJR Am J Roentgenol; 2018 Mar; 210(3):615-620. PubMed ID: 29323547
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing Untreated Osteoblastic Metastases From Enostoses Using CT Attenuation Measurements.
Ulano A; Bredella MA; Burke P; Chebib I; Simeone FJ; Huang AJ; Torriani M; Chang CY
AJR Am J Roentgenol; 2016 Aug; 207(2):362-8. PubMed ID: 27101076
[TBL] [Abstract][Full Text] [Related]
4. CT Attenuation Values Do Not Reliably Distinguish Benign Sclerotic Lesions From Osteoblastic Metastases in Patients Undergoing Bone Biopsy.
Azar A; Garner HW; Rhodes NG; Yarlagadda B; Wessell DE
AJR Am J Roentgenol; 2021 Apr; 216(4):1022-1030. PubMed ID: 32755207
[No Abstract] [Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. The utility of 2-[
Sebro R; Ashok SS
Eur Radiol; 2021 Sep; 31(9):6780-6792. PubMed ID: 33686475
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
8. Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ-based Comparison With PET/CT.
Pujara AC; Raad RA; Ponzo F; Wassong C; Babb JS; Moy L; Melsaether AN
Breast J; 2016 May; 22(3):264-73. PubMed ID: 26843433
[TBL] [Abstract][Full Text] [Related]
9. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
[TBL] [Abstract][Full Text] [Related]
10. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
Watanabe H; Kanematsu M; Goshima S; Kondo H; Kawada H; Noda Y; Moriyama N
Ann Nucl Med; 2013 Aug; 27(7):648-53. PubMed ID: 23625579
[TBL] [Abstract][Full Text] [Related]
11. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
12. Bone islands incidentally detected on computed tomography: frequency of enostosis and differentiation from untreated osteoblastic metastases based on CT attenuation value.
Sala F; Dapoto A; Morzenti C; Firetto MC; Valle C; Tomasoni A; Sironi S
Br J Radiol; 2019 Nov; 92(1103):20190249. PubMed ID: 31469323
[TBL] [Abstract][Full Text] [Related]
13. Ability of
Ou X; Wang J; Zhou R; Zhu S; Pang F; Zhou Y; Tian R; Ma X
Contrast Media Mol Imaging; 2019; 2019():4507694. PubMed ID: 30930700
[No Abstract] [Full Text] [Related]
14.
Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
[TBL] [Abstract][Full Text] [Related]
15. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of
Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
[TBL] [Abstract][Full Text] [Related]
17. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
18. The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.
Nakajo M; Nakajo M; Jinguji M; Fukukura Y; Nakabeppu Y; Tani A; Yoshiura T
Br J Radiol; 2015; 88(1055):20150552. PubMed ID: 26337605
[TBL] [Abstract][Full Text] [Related]
19. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
20. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
Brady MJ; Thomas J; Wong TZ; Franklin KM; Ho LM; Paulson EK
Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
